



November 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2014-001639-35/ Novartis Protocol ID CRFB002DDE25

A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis

Trial CRFB002DDE25 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.